Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-411 in Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CASCA)
NCT06798012Phase 2Recruiting
- Sponsor
- Takeda
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 3
01
Overview
A Phase 2 trial of m254 in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by Takeda. Started May 2025; status: recruiting.
02
Drugs
m254
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06798012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06798012.